|
|
|
|
|
Sponsored by: |
University of Oklahoma |
Information provided by: | University of Oklahoma |
ClinicalTrials.gov Identifier: | NCT00728650 |
This study will review the treatment and outcomes of patients having primary and metastatic hepatic malignancies. Patients treated with surgical resection, percutaneous radiofrequency ablation (RFA), and transarterial chemoembolization (TACE) will be compared with patients not receiving these treatments. Tumor recurrence and survival data will be compared to the published literature to determine the efficacy of current treatment strategies in this patient population.
Condition |
Liver Cancer |
MedlinePlus related topics: | Cancer Liver Cancer |
Study Type: | Observational |
Study Design: | Other, Retrospective |
Official Title: | A Retrospective Review of Malignant Liver Tumors |
Estimated Enrollment: | 500 |
Study Start Date: | October 2003 |
Estimated Study Completion Date: | October 2010 |
Estimated Primary Completion Date: | October 2010 (Final data collection date for primary outcome measure) |
Groups/Cohorts |
Observation
Patients with primary or metastatic hepatic malignancies
|
Subjects will be identified by diagnosis and procedure codes from a university surgical practice and the St. John Medical Center Cancer Registry. Data will be obtained by review of both the clinic and hospital charts. In addition we plan to review and utilize liver tumor treatment and outcomes data from a national database. Treatment decisions, in cases managed by the primary investigator, were made on a clinical basis, often in collaboration with an interventional radiologist. Of the patients managed by the principal investigator, all procedures were undertaken after an informed consent process. Subjects were not exposed to risk beyond that posed by the recommended treatment. All treatments were within the scope of standard medical care. The primary investigator has no knowledge of the treatments chosen for the patients he did not manage. The subject's referring physician may be contacted to obtain follow-up data on the subject. The follow-up data will include: is the patient alive with disease; alive without disease, alive unknown; dead free of disease; dead with disease; dead unknown.
Ages Eligible for Study: | 20 Years to 90 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Primary care clinic and patients treated at St. John Medical Center in Tulsa, OK
Inclusion Criteria:
Exclusion Criteria:
United States, Oklahoma | |||||
The University of Oklahoma College of Medicine, Tulsa - Department of Surgery | |||||
Tulsa, Oklahoma, United States, 74135 |
University of Oklahoma |
Principal Investigator: | Thomas A Broughan, MD | University of Oklahoma-Tulsa |
Responsible Party: | The University of Oklahoma College of Medicine, Tulsa ( Thomas A. Broughan, MD Professor and Chair ) |
Study ID Numbers: | TAB11119 |
First Received: | August 1, 2008 |
Last Updated: | August 1, 2008 |
ClinicalTrials.gov Identifier: | NCT00728650 |
Health Authority: | United States: Institutional Review Board |
|
|
|
|